Side-by-side · Research reference
CagrilintidevsIGF-DES
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED35/64 cited
BAnimal-StrongHUMAN-REVIEWED8/60 cited
IGF-DES
IGF-1 Analogue · Truncated N-Terminal
~10×Potency vs IGF-1
ReducedIGFBP binding
ResearchStatus
Injection (local or systemic) · Research protocols onlyBredehöft 2008
01Mechanism of Action
Parameter
Cagrilintide
IGF-DES
Primary target
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
IGF-1 receptor (IGF1R)Shields 2007
Pathway
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation
Downstream effect
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation
Feedback intact?
Yes — acts via physiological amylin pathways
Unknown — no human endocrine feedback data
Origin
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008
Antibody development
—
—
02Dosage Protocols
Parameter
Cagrilintide
IGF-DES
Standard dose (combination)
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
—
Monotherapy dosing
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
—
Frequency
Once weekly (subcutaneous)Bailey 2026
Long-acting formulation.
Variable — daily to multiple times daily in research
Evidence basis
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
Animal models + in vitro only
Route
Subcutaneous injectionBailey 2026
Subcutaneous or intramuscular (local injection favored)
Local delivery maximizes tissue-specific uptake.
Research dose range
—
10–100 ng/mL (in vitro); μg doses (animal models)
Highly context-dependent; no standardized human protocol.
Human data
—
None — no clinical trials
Half-life
—
Shorter than IGF-1 due to reduced IGFBP binding
Rapid tissue uptake, limited systemic circulation.
03Metabolic / Fat Loss Evidence
Parameter
Cagrilintide
IGF-DES
Weight loss vs semaglutide
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
—
Absolute weight change
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
—
Glycemic benefit
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
—
Body composition
Predominant fat loss with weight reduction
—
Mitochondrial function
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
—
Key publications
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
—
Primary mechanism
—
Indirect via muscle hypertrophy → metabolic rate elevation
Direct lipolysis
—
Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic
Prostate model
—
Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002
Context-specific anti-proliferative effect, not fat loss.
04Side Effects & Safety
Parameter
Cagrilintide
IGF-DES
Gastrointestinal
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
—
Injection site reactions
Local reactions possible with subcutaneous administration
—
Safety profile
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
—
Tolerability
Tolerability considerations similar to GLP-1RAs
—
Muscle preservation
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
—
Hypoglycemia risk
—
Theoretical — IGF-1 axis enhances glucose uptake
Mitogenic risk
—
Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002
Injection site reaction
—
Expected — erythema, irritation, local swelling
Edema / Fluid retention
—
Possible via sodium retention (IGF-1 axis effect)
Human safety data
—
Absent — no human trials, all effects theoretical or extrapolated
Unknown long-term effects
—
No chronic dosing studies in humans; endocrine, metabolic consequences unknown
Absolute Contraindications
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
IGF-DES
- ·Active malignancy or history of cancer (mitogenic risk)
- ·Pregnancy / lactation (no safety data)
- ·Hypoglycemia disorders
Relative Contraindications
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
IGF-DES
- ·Diabetes mellitus (unpredictable glucose effects)
- ·Renal or hepatic impairment (clearance unknown)
- ·Edema-prone conditions (heart failure, nephrotic syndrome)
05Administration Protocol
Parameter
Cagrilintide
IGF-DES
1. Dosing frequency
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.
2. Combination form
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.
3. Injection site
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.
4. Storage
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.
5. Dietary considerations
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.
6. Monitoring
—
Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.
06Stack Synergy
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation
IGF-DES
+ BPC-157
ModerateDes(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- BPC-157
- 250–500 mcg SQ, daily or twice daily
- Frequency
- Daily or per research protocol
- Primary benefit
- Accelerated muscle repair, enhanced hypertrophy, connective tissue support
+ TB-500
ModerateTB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- TB-500
- 2–5 mg SQ, 2× weekly
- Frequency
- Per research cycle
- Primary benefit
- Muscle hypertrophy, injury recovery, vascular support